Navigation Links
Cancer: Trapping the escape artist
Date:5/11/2010

LA JOLLA, Calif., May 11, 2010 -- Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

In a paper published online in the journal Cell Death and Disease on May 6, Maurizio Pellecchia, Ph.D., and colleagues outline how the six anti-apoptotic proteins in the Bcl-2 family are expressed differently in different cancers. As a result, any therapy designed to defeat these proteins, and thus enhance the cell death caused by most cancer treatments, must target the exact anti-apoptotic protein the cancer is expressing to be effective. However, even targeting the right protein might not be enough, as cancers often express more than one and can select for an "escape" protein and continue to thrive.

"You need to inhibit all six of the anti-apoptotic proteins members of the Bcl-2 family to have a compound with therapeutic potential," says Dr. Pellecchia.

Related research may have solved that problem. The Pellecchia laboratory, in collaboration with Coronado Biosciences and Virginia Commonwealth University, has been working on just such a pan-Bcl-2 inhibitor, and may have found it in a compound called BI-97C1. A paper published online on May 5 in the Journal of Medicinal Chemistry describes how BI-97C1, an optically pure derivative of a cottonseed extract called gossypol, inhibits all six anti-apoptotic Bcl -2 family proteins. This broad spectrum approach could make current cancer treatments more effective by controlling all six of these proteins and allowing malignant cells to die.

"When we tested BI-97C1 against human prostate cancer in mice, the cancer was completely wiped out, even with one tenth the dose we had used with previous compounds," says Dr. Pellecchia.

BI-97C1 is currently licensed to Coronado Biosciences, a private, clinical stage biotech company focused on new cancer treatments. Coronado's pan Bcl-2 inhibitor program is expected to enter clinical trials soon. "We have a very productive collaboration with Dr. Pellecchia," says R.J. Tesi, M.D., president and CEO of Coronado Biosciences. "His work demonstrates the importance of inhibiting all six Bcl-2 pro-survival proteins and demonstrates how rational drug design can optimize the development of targeted therapies to treat cancer. We are anxious to move BI-97C1 from pre-clinical development into patients."


'/>"/>

Contact: Josh Baxt
jbaxt@sanfordburnham.org
858-795-5236
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Related biology news :

1. Prostate cancer: Watchful wait or vaccinate?
2. Scientists discover how cigarette smoke causes cancer: Study points to new treatments, safer tobacco
3. Stem cells and cancer: cancer pathways that also control the adult stem cell population
4. Hispanic women and breast cancer: An understudied group
5. Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
6. Cancer: Another step towards medication
7. Early detection of lung cancer: New data presented at multidisciplinary meeting
8. From cars to cancer: UH professor employs auto industry tools for tumor therapy
9. Cancer: The cost of being smarter than chimps?
10. Cancer: Primitive gene discovered
11. Milk and risk of renal cell cancer: Genetic research sheds new light
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... ... April 25, 2017 , ... Leaders of Quorum ... will be featured in multiple sessions at this week’s Association of Clinical Research ... to best practices in clinical research. , "We are excited to present subject matter ...
(Date:4/21/2017)... ... April 21, 2017 , ... The 2017 Colorado ... with over 30 nominees and well as the first-year award for 2017 Manufacturing ... the event was hosted by CompanyWeek and Manufacturers Edge, among other sponsors. ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... related applications were the focus of researchers, engineers, product developers, and industry suppliers ... Anaheim. , Sponsored by SPIE, the international society for optics and photonics ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... to nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant ... location. , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit ...
Breaking Biology Technology: